Replies to post #37104 on Pluristem Therapeutics Inc (PSTI)

[midastouch017]

I believe it was forthright; but not near term encouraging.

I fully agree. There is nothing to
wait for until end Q3. What will
happen after that is anybody's take.

The fact that nobody on this board
attempted to relay or reply to my
#msg-157045166 makes me think this
is more a cult than an investors
discussion board. If one does not
cheerlead the company, one is bound
to be insulted and shushed!

Todays letter was very informative, but
i cannot forsee any new investors
rushing in to buy, as nearterm there
is nothing exciting about to happen.
MHO

[zzaatt]

Zzaat- Your're the voice of reason on this board.

LOL!
Thanks for the compliment, but my only claim to fame is that I tend to dismiss daily fluctuations in the PPS and bombshells (like a new shelf) and instead try to concentrate on basic rationale of investing in this technology (stem cells) AND specific company.

Having said that, I'm very interested in the management maintaining company's financial health, and I do want to see indications/hints that the science and implementation is proceeding as it should. In that regard, I'm very confident!!!

As far as the "update", I don't see anything terribly significant. If you expected game changing news, then obviously it's a disappointment.

My take on it is that they're NOT promising any specific (to the day) news event, in the next few weeks. On the other hand, we've had numerous unexpected and very (potentially) significant news, such as the very fact of the Covid opportunity, then, information on compassionate use (the official one), AND excellent results in individual cases.

We had financial news ($50 mill) from Eu and as a result we're in good shape for three years.

I would bet that there will be unexpected (hopefully) good news even before the official end dates for ongoing trials.

A great deal of my patience with the company comes from an appreciation of the incredible scientific advance their technology represents and the associated challenges (scientific, regulatory, medical). ALSO, as I've said before, I don't think management is in any position to force the clinical/regulatory apparatus to hurry up. I suspect that Pluristem is as anxious for progress as Midas (btw, you don't have to be a "booster", healthy skepticism is of benefit to all of us).

Bottom line: a little more patience, if we do get good results in any one of the current indications, we will all feel the wait was worth it.

PS (hopester, I responded to you in a prev. note that was removed, I hope you got to see it)